Please login to the form below
lebrikizumab
This page shows the latest lebrikizumab news and features for those working in and with pharma, biotech and healthcare.
Dermira craters as acne drug fails late-stage test
Also in its pipeline is an injectable drug for atopic dermatitis - I L-13 inhibitor lebrikizumab - which was developed by Roche and licensed to Dermira in a deal valued at up ... That programme is in mid-stage clinical testing. Even if it successfully
Latest news
-
Setback for AZ as tralokinumab flunks asthma trial
The failure of tralokinumab hasn’t come out of the blue, as another trial (STRATOS 1) also failed to hit the mark, and other IL-13 inhibitors - including Roche’s lebrikizumab
-
Roche out-licenses lebrikizumab rights to Dermira
Roche has opted to out-license the bulk of the rights to its IL-13 inhibitor lebrikizumab to dermatology company Dermira in a deal valued at up to $1.4bn. ... The deal includes rights to lebrikizumab for atopic dermatitis and all other indications with
-
AZ trial adds to pessimism about anti-IL-13 asthma drugs
It looks increasingly like a lost cause as AZ already reported disappointing phase IIb data with tralokinumab, and last year Roche reported disappointing results with its anti-IL-13 candidate lebrikizumab,
-
Teva gets EU nod for severe asthma drug Cinqaero
13 inhibitor lebrikizumab.
-
Roche shares slip as profits miss expectations
Aside with atezolizumab, Roche is also looking ahead to possible launches for multiple sclerosis candidate ocrelizumab - also due for filing shortly - as well as asthma drug lebrikizumab.
More from news
Approximately 2 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Pharma deals during August 2014
This brings a much needed boost to its respiratory portfolio, which currently consists of Pulmozyme (cystic fibrosis) and Xolair (severe asthma) and products in clinical development, eg lebrikizumab (severe asthma).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
-
Account Director – UK Office
-
Excellent salary and benefits
- Account Director, Healthcare Communications
-
Salary TBC
Subscribe to our email news alerts
- Finch Therapeutics bags $53m for microbiome therapies
- MSD taps Austria’s Themis to bolster vaccine pipeline
- Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
- GSK preps filings for BCMA-targeting multiple myeloma drug
- Behaviour change – is there something missing?
- NICE’s long-serving chief exec Sir Andrew Dillon to step down
PMHub
Complete Medical Communications (CMC)
CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
